To evaluate the clinical implications of CD133 expression, we investigated the correlations between CD133 expression and the clinicopathological findings, such as tumor grade, Dukes classification, lymph node metastasis, lymphatic invasion and venous invasion (Table 2). This evidence concerns the gene PROM1 and metastatic malignant neoplasm in the lymph nodes.